NCT05241392View on ClinicalTrials.gov

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

December 31, 2026

Conditions
Glioblastoma
Interventions
BIOLOGICAL

B7-H3-targeting CAR-T cells

Patients will be treated with anti-B7-H3 autologous CAR-T cells that are delivered into the intracranial tumor resection cavity or ventricular system using an Ommaya device.

Trial Locations (1)

100730

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER